Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ascendis Pharma ( (ASND) ) just unveiled an update.
On February 12, 2025, Ascendis Pharma announced its financial results for the year ending December 31, 2024. The company reported significant revenue growth, driven by the strong launch of YORVIPATH in the U.S. and anticipated further expansion in Europe. SKYTROFA has solidified its leading position in the U.S. growth hormone market. Ascendis plans to submit an NDA for TransCon CNP for achondroplasia in Q1 2025 and expand its product pipeline with new trials and market launches in 2025. The company also entered into an exclusive licensing agreement with Novo Nordisk, strengthening its financial position and supporting its vision to become a leading biopharmaceutical company with multiple blockbuster products.
More about Ascendis Pharma
Ascendis Pharma A/S is a global biopharmaceutical company based in Denmark, known for its innovative therapies in endocrinology and oncology. Their primary products include YORVIPATH for hypoparathyroidism and SKYTROFA for growth hormone deficiency, with a focus on achieving a leading position in these markets.
YTD Price Performance: -13.40%
Average Trading Volume: 450,810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $7.14B
For detailed information about ASND stock, go to TipRanks’ Stock Analysis page.
